Market Overview

GW Pharmaceuticals Shares Jump Following Price Target Raise

Related GWPH
Goldman Sachs Sees 40% Upside In GW Pharmaceuticals
Benzinga's Top Upgrades, Downgrades For December 14, 2017
ROTY Edition 1 Volume 63: Argenx' Successful Offering, Amicus Submits NDA And Other Updates (Seeking Alpha)

In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy.

The analysts at Piper Jaffray say that the unique safety/CNS profile make the drug an attractive way to treat epilepsy.

Additionally, the analysts noted that they do not believe INSYS Therapeutics will be able to compete on price.

Following the note, shares of GW Pharmaceuticals are up over six percent in the pre-market.

Latest Ratings for GWPH

Dec 2017Goldman SachsUpgradesNeutralBuy
Nov 2017Bank of AmericaMaintainsBuy
Oct 2017Leerink SwannMaintainsOutperform

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color News Price Target Analyst Ratings


Related Articles (GWPH)

View Comments and Join the Discussion!